Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel R Denmeade

Showing results (51-60 of 155) with videos related to

Pageof 16
Sort By:
Journal of the National Cancer Institute|August 23, 2012
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrugW Nathaniel Brennen, D Marc Rosen, Hao Wang, et al.
Bioorganic & Medicinal Chemistry|June 23, 2009
Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancerAaron M LeBeau, Sangeeta R Banerjee, Martin G Pomper, et al.
Prostate Cancer and Prostatic Diseases|May 7, 2024
Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trialMayuko Kanayama, Hua-Ling Tsai, Hao Wang, et al.
Cancer Biology & Therapy|August 14, 2008
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)Sachin S Chandran, Sangeeta R Banerjee, Ron C Mease, et al.
The Prostate|January 9, 2010
Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic miceSimon A Williams, Yi Xu, Angelo M De Marzo, et al.
Bioorganic & Medicinal Chemistry|May 16, 2007
Modulating paclitaxel bioavailability for targeting prostate cancerSrinivas K Kumar, Simon A Williams, John T Isaacs, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2013
Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasmaMichael L Manning, Simon A Williams, Christine A Jelinek, et al.
The Prostate|June 9, 2016
Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA ZymogenNiquiche Sangster-Guity, Becky Tu-Sekine, Daniel M Raben, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2023
Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancerLaura A Sena, Tingchang Wang, Hao Wang, et al.
Cancer Research|February 28, 2002
Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblastsJacek Pinski, Ashani Weeraratna, Aarti R Uzgare, et al.
Pageof 16

Showing results (51-60 of 155) with videos related to

Sort By:
Pageof 16
Journal of the National Cancer Institute|August 23, 2012
Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrugW Nathaniel Brennen, D Marc Rosen, Hao Wang, et al.
Bioorganic & Medicinal Chemistry|June 23, 2009
Optimization of peptide-based inhibitors of prostate-specific antigen (PSA) as targeted imaging agents for prostate cancerAaron M LeBeau, Sangeeta R Banerjee, Martin G Pomper, et al.
Prostate Cancer and Prostatic Diseases|May 7, 2024
Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trialMayuko Kanayama, Hua-Ling Tsai, Hao Wang, et al.
Cancer Biology & Therapy|August 14, 2008
Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA)Sachin S Chandran, Sangeeta R Banerjee, Ron C Mease, et al.
The Prostate|January 9, 2010
Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic miceSimon A Williams, Yi Xu, Angelo M De Marzo, et al.
Bioorganic & Medicinal Chemistry|May 16, 2007
Modulating paclitaxel bioavailability for targeting prostate cancerSrinivas K Kumar, Simon A Williams, John T Isaacs, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 13, 2013
Proteolysis of complement factors iC3b and C5 by the serine protease prostate-specific antigen in prostatic fluid and seminal plasmaMichael L Manning, Simon A Williams, Christine A Jelinek, et al.
The Prostate|June 9, 2016
Mutational Analysis of Prostate-Specific Antigen Defines the Intrinsic Proteolytic Activity of the proPSA ZymogenNiquiche Sangster-Guity, Becky Tu-Sekine, Daniel M Raben, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2023
Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancerLaura A Sena, Tingchang Wang, Hao Wang, et al.
Cancer Research|February 28, 2002
Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblastsJacek Pinski, Ashani Weeraratna, Aarti R Uzgare, et al.
Pageof 16